The review concluded that intra-articular corticosteroid injections were significantly and clinically efficacious in reducing pain caused by knee osteoarthritis. The review was generally of poor quality and the authors' conclusions are not likely to be reliable.
authors stated that some studies used inadequate randomisation methods. Four RCTs that compared different types of corticosteroid were also included (total sample size unknown, range was 32 to 57 participants). Three of these trials were double-blind. One study confirmed needle placement within the joint by fluid aspiration.
Corticosteroids versus placebo: Follow-up ranged from two to 24 weeks. Four RCTs reported statistically significant differences in pain reduction after one week that favoured corticosteroid treatment (the mean reduction was 22 points on a zero to 100 scale). No significant pain differences between groups were seen at three or four weeks (four studies) and six to eight weeks (four studies). At week four, one study reported a significant difference from baseline in the corticosteroid group, but not in the placebo group. One study reported no significant pain differences between groups at 12 and 24 weeks.
Comparisons of different corticosteroids: Two of three studies that compared triamcinolone with methylprednisolone reported no statistically significant differences between groups; the third study found triamcinolone to be significantly more effective at reducing pain at week three (p<0.01). One study found triamcinolone to be significantly more effective than betamethasone at week one.
Authors' conclusions
Intra-articular corticosteroid injections were significantly and clinically efficacious at reducing knee osteoarthritis pain for at least one week. From the limited studies available, triamcinolone appeared to be more efficacious than either betamethasone or methylprednisolone.
CRD commentary
Although the review addressed a clear question, the inclusion criteria related only to placebo-controlled trials; therefore, the authors included studies that did not satisfy the inclusion criteria and the methods used to identify these studies were unclear. Placebo-controlled studies were identified by searching electronic databases and checking references. Only studies in English were included and it was unclear whether unpublished studies were sought, so relevant trials may have been missed and the review may have been subject to publication and language biases. The authors did not report that they used methods (such as independent duplicate study selection and data extraction) to minimise the risk of reviewer error and bias during the review process. Details of the methods and results of the basic study quality assessment used were too incomplete to allow a full assessment of the reliability of the included studies. It appeared that some studies had methodological flaws and all had small sample sizes, so the possibility of chance results could not be ruled out.
A narrative synthesis was performed. The importance of individual studies appeared to be weighted equally; the authors did not comment on whether use of meta-analysis may have been appropriate. Tabulated details were provided, but only for the placebo-controlled studies. No definition of what might constitute a clinically important difference was given.
This review was poor in both its methodology and reporting. The authors' conclusions are not likely to be reliable.
Implications of the review for practice and research
Practice: The authors stated that corticosteroids may be incorporated into clinical practice for the short-term relief of knee osteoarthritis symptoms. They added that before using corticosteroids for chronic symptoms in knee osteoarthritis, physicians should be aware that the benefit is short-term and other treatments should be considered for longer-term pain reduction.
Research: Further studies were needed to compare different corticosteroids; they would benefit from standard validated outcome measures and standardised doses and follow-up time points.
